Key result
Remimazolam cuts hypotension risk ~29% vs propofol during anesthesia induction in hypertensive patients.
Why the study?
Does remimazolam reduce the incidence of hypotension and bradycardia compared to propofol during anesthesia induction in hypertensive patients?
Meta-Analysis (n=484)
Does remimazolam reduce the incidence of hypotension and bradycardia compared to propofol during anesthesia induction in hypertensive patients?
Remimazolam may provide superior hemodynamic stability compared to propofol during anesthesia induction in hypertensive patients, though larger trials are needed to confirm these findings.
Answers are grounded in this paper and cite their sources.
May warrant remimazolam preference over propofol for induction in hypertensives; hypothesis-generating pending larger confirmatory trials.
The administration of remimazolam showed a trend toward superior hemodynamic stability compared with propofol during anesthesia induction in hypertensive patients, especially in minimizing the incidence of hypotension and bradycardia. However, the trial sequential analysis results remain inconclusive, the current evidence is limited by small sample sizes, and larger trials are needed to confirm our findings.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) conducted a meta-analysis in Hypertension (n=484). Remimazolam vs. Propofol was evaluated on Incidence of hypotension (RR 0.711, 95% CI 0.545-0.929). Remimazolam lowered the risk of hypotension and bradycardia compared with propofol during anesthesia induction in hypertensive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: